Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: highly expressed protein in malignant tumors of epithelial origin. It has been registered for head and neck tumors since 2002. To determine the effectiveness of Nimotuzumab in head and neck cancer through the combined meta-analysis technique. A search was conducted in PubMed, in an indexed magazine with the words “Nimotuzumab”, “head and neck,” 48 articles published by Cuban and foreign authors were detected between April 1, 2005, and July 31, 2019, in which the results of clinical studies conducted with the monoclonal antibody Nimotuzumab are described. Seven clinical trials conducted in Cuba from 2005-2019 with Nimotuzumab are described; three Phase I / II (with 14, 10 and 10 patients respectively), a Phase II / III with 106 patients, a Phase II with 37 patients, two Phase IV (with 386 and 225 patients each) and a study promoted by the Researcher with 17 patients. From these studies, the three controlled trials were selected by the PRISMA flow chart. The meta-analysis consisted of the construction of the Forest Plot graph, the sensitivity analysis and the cumulative analysis. The meta-analysis shows favorable results for Nimotuzumab, without heterogeneity (I2 = 0%). The sensitivity analysis reveals that the test that differs most from the others is Phase II / III. The cumulative analysis indicates that after the second trial, there is already sufficient evidence.
Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: highly expressed protein in malignant tumors of epithelial origin. It has been registered for head and neck tumors since 2002. To determine the effectiveness of Nimotuzumab in head and neck cancer through the combined meta-analysis technique. A search was conducted in PubMed, in an indexed magazine with the words “Nimotuzumab”, “head and neck,” 48 articles published by Cuban and foreign authors were detected between April 1, 2005, and July 31, 2019, in which the results of clinical studies conducted with the monoclonal antibody Nimotuzumab are described. Seven clinical trials conducted in Cuba from 2005-2019 with Nimotuzumab are described; three Phase I / II (with 14, 10 and 10 patients respectively), a Phase II / III with 106 patients, a Phase II with 37 patients, two Phase IV (with 386 and 225 patients each) and a study promoted by the Researcher with 17 patients. From these studies, the three controlled trials were selected by the PRISMA flow chart. The meta-analysis consisted of the construction of the Forest Plot graph, the sensitivity analysis and the cumulative analysis. The meta-analysis shows favorable results for Nimotuzumab, without heterogeneity (I2 = 0%). The sensitivity analysis reveals that the test that differs most from the others is Phase II / III. The cumulative analysis indicates that after the second trial, there is already sufficient evidence.
RESUMENIntroducción: Los cuidados de nutrición durante los primeros años de vida son fundamentales para el óptimo crecimiento y desarrollo del niño. Objetivo: Evaluar los conocimientos, actitudes y prácticas alimentarias de las madres con niños de 6 a 24 meses de edad en San Cristóbal, Artemisa, 2015. Material y Métodos: Se realizó un estudio descriptivo transversal con 95 madres de niños entre 6 y 24 meses de edad, pertenecientes a las 13 áreas de salud de la localidad de San Cristóbal. Se aplicó el cuestionario diseñado y validado por el Instituto Nacional de Nutrición e Higiene de los Alimentos para el Estudio Nacional sobre Hábitos y Prácticas Alimentarias de los niños menores de dos años. Resultados: Se encontró desconocimiento del valor nutritivo de las grasas (53,7%), y de los riesgos del consumo de gelatina (88,4%). El 80% de las madres utilizaba el biberón para alimentar a sus hijos, y el 71,6% ofrecía los alimentos mezclados. Conclusiones: No todas las madres tenían conocimientos adecuados sobre los alimentos que debían dar al niño a partir del primer año de vida. La mayoría mantuvo actitudes favorables y buenas prácticas durante la alimentación de sus hijos, con excepción del uso de biberón. ABSTRACT Introduction:The cares of nutrition during the first years of life are critical for optimal growth and development of the child. Objective: To evaluate the knowledge, attitudes and practices of mothers with children from 6 to 23 months of age in San Cristobal, Artemisa, 2015. Methods: A descriptive and transversal investigation was done with 95 mothers of children between 6 and 24 months of age, belonging to the 13 health areas of the town of San Cristobal. Questionnaire was designed and validated by the National Institute of Nutrition and Food Hygiene to the National Survey on Dietary Habits and Practices of children under the age of two years. Results There was a lack of knowledge of the nutritional value of fats (53.7%) and of the risks of gelatin consumption (88.4%). 80% of mothers used the bottle to feed their children, and 71.6% offered mixed foods. Conclusions: Not all mothers had adequate knowledge about foods that should give the child from the first year of life. The majority maintained favorable attitudes and good practices during the feeding of their children, except for the use of bottle.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.